Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma. © 2007 Springer-Verlag.
CITATION STYLE
Terheyden, P., Hofmann, M. A., Weininger, M., Bröcker, E. B., & Becker, J. C. (2007). Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. Journal of Cancer Research and Clinical Oncology, 133(11), 897–901. https://doi.org/10.1007/s00432-007-0251-8
Mendeley helps you to discover research relevant for your work.